Brandon Scalea

By better understanding the subtypes of breast cancer, clinicians can create more personalized and effective treatment plans for patients with breast cancer.

Monoclonal antibodies, proteasome inhibitors, and targeted agents are among the many options in the crowded treatment landscape of relapsed/refractory multiple myeloma, and the emergence of drugs, such as venetoclax (Venclexta) and selinexor, could add to the complexity of this paradigm, said Cristina Gasparetto, MD.

Certain patients with colorectal cancer may see a cure thanks to new, tailored approaches.

The PD-1 inhibitor pembrolizumab (Keytruda) has shown an overall survival advantage across 3 phase III clinical trials studying its use in patients with metastatic non–small cell lung cancer (NSCLC). These positive results led to a frontline indication as a single agent and in combination with chemotherapy for both patients with squamous and nonsquamous NSCLC.

As the cost of cancer therapies continues to increase, the cancer community is looking to biosimilars as a potential alternative for treatment; however, experts wonder if factors besides cost need to be taken in to consideration.

African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated similar overall survival (OS) rates, according to study results presented at the 2018 ASCO Annual Meeting.